Exsitec Holding AB (FRA:1TI)

Q1 2025 Exsitec Holding AB Earnings Call Transcript

Apr 23, 2025 / 08:00 AM GMT

Release Date Price: €10 (+8.23%)

Transcript

Key Points

Positve

Exsitec Holding AB (OSTO:EXS) reported a return to profitable growth in 2024, with group net sales growing organically by 2% to €21.2 billion.
The company achieved a 6.9% organic increase in EBITA, reaching €6.1 billion, reflecting strong operational performance.
Healthcare sector was the best performer with 7% organic sales growth, driven by oncology and cardiovascular metabolism and endocrinology franchises.
Exsitec Holding AB (OSTO:EXS) made strategic investments to enhance production and R&D capabilities across key markets, including the US, Europe, and Asia Pacific.
The company is committed to sustainability, having reduced direct and indirect greenhouse gas emissions by 26% since 2020, with a target to cut emissions by 50% by 2030.

Negative

Life Science sector experienced a decline in full-year sales by 3.3% to €8.9 billion, impacted by inventory destocking and tough year-over-year comparables post-COVID-19.
Sales in the Life Science Services business unit declined by 9% organically in 2024.
The process solution business unit saw an organic full-year sales decline of 6.4%, despite good order intake in Q4.
The company faced a setback with Sabina Pan, an asset investigated for treating head and neck cancer, which did not meet expectations.
Electronics sector's display solutions and surface solutions business units recorded expected sales declines, indicating challenges in these areas.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EXS.ST - Exsitec Holding AB
Q1 2025 Exsitec Holding AB Earnings Call
Apr 23, 2025 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, let me extend a warm welcome to all of you on behalf of the supervisory board and the executive board. I now open today's 2025 annual general meeting of Merck KGAA. My name is Michael Kleinmeyer, and as Chairman of the supervisory board, I assume the chair of this AGM. Let me first of all welcome our shareholders and shareholder representatives. I would also like to welcome. The representatives of the media, I am happy about the interest you're taking in our company. This AGM is being held in a virtual format. The company's executive board has carefully deliberated this decision. A virtual format requires less effort for participating in the meeting, and the virtual format also helps to reduce environmental impact.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.